Dexmedetomidine for Bilateral Superficial Cervical Plexus Block for Reconstructive Tracheal Surgery
Status:
Completed
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
Tracheal resection and reconstruction (TRR) is the treatment of choice for most patients with
tracheal stenosis or tracheal tumors .The post intubation tracheal stenosis is the common
indication for (TRR).The immediate postoperative period can be anxiety provoking for some
reasons such as requirement to maintain a flexed neck, oxygen mask, and surgical pain which
inadequately treated.
Bilateral superficial cervical plexus block (BSCPB) is a popular regional anesthesia
technique for its feasibility and efficacy. The use of regional anesthesia in combination
with general anesthesia may lighten the level of general anesthesia required , provide
prolonged postoperative analgesia and reduce the requirements for opioid analgesics
Dexmedetomidine is a highly selective α2 agonist with high affinity for α2 adrenergic
receptors and less α1 effects, which is responsible for the hypnotic and analgesic effects.
Previous trials demonstrated that perineural dexmedetomidine in combination with bupivacaine
enhanced sensory and motor block ,without neurotoxicity ,in both experimental and clinical
studies.
Levobupivacaine, is "S"-enantiomer of bupivacaine, has strongly emerged as a safer
alternative for regional anesthesia than bupivacaine . Levobupivacaine has been found to be
equally efficacious as bupivacaine, but with a superior pharmacokinetic profile.
Clinically, levobupivacaine has been observed to be well tolerated in regional anesthesia
techniques both after bolus administration and continuous post-operative infusion.